Studying the FCRL5 protein in people with multiple sclerosis
Looks at the FCRL5 protein in blood and spinal fluid of people with multiple sclerosis.
Plain-language title generated from the registry record
Registry title: The Role of the FCRL5 Protein in the Pathophysiology of Multiple Sclerosis and Response to Treatment
Key facts
- Where
- Brussels, BelgiumSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07788573, who can take part
Where in Belgium
- Université Catholique de LouvainBrussels, BelgiumNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Université Catholique de Louvain
- Trial code
- NCT07788573
- Record updated
- 4 November 2026
- Original description
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system (CNS) and the leading non-traumatic cause of neurological disability in young adults. Historically considered a T-cell-mediated disease, the paradigm for MS has shifted thanks to the efficacy of therapies targeting B cells. The investigators recently identified FCRL5 as a B-cell-specific biomarker that is significantly elevated in the cerebrospinal fluid (CSF) of patients with relapsing-remitting MS and is independently associated with an increased risk of developing new MRI lesions within two years of diagnosis (ref. Deltombe et al., PMID: 41004694). This project aims to further explore FCRL5 as a prognostic biomarker, study the role of FCRL5-expressing B cells in MS pathogenesis and the effects of disease-modifying therapies on these subsets.Read full original descriptionShow less
The Role of the FCRL5 Protein in the Pathophysiology of Multiple Sclerosis and Response to Treatment
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system (CNS) and the leading non-traumatic cause of neurological disability in young adults. Historically considered a T-cell-mediated disease, the paradigm for MS has shifted thanks to the efficacy of therapies targeting B cells. The investigators recently identified FCRL5 as a B-cell-specific biomarker that is significantly elevated in the cerebrospinal fluid (CSF) of patients with relapsing-remitting MS and is independently associated with an increased risk of developing new MRI lesions within two years of diagnosis (ref. Deltombe et al., PMID: 41004694). This project aims to further explore FCRL5 as a prognostic biomarker, study the role of FCRL5-expressing B cells in MS pathogenesis and the effects of disease-modifying therapies on these subsets.
Inclusion: For MS patients:; Male or female; Between 18 and 80 years of age; Diagnosed with MS according to the most recent McDonald criteria (2025); Patients who are about to start a new MS treatment or switch treatments; For healthy volunteers:; Men or women; Ages 18 to 80; Healthy volunteers with no neurological conditions or autoimmune diseases; For participants with Sjögren's syndrome:; Men or women; Ages 18 to 80.
Exclusion: No recent relapse (during the 3 months prior to study enrollment); Patients treated with corticosteroids (during the 3 months prior to study enrollment); Patients receiving another immunosuppressive therapy unrelated to MS; Inability to sign the informed consent form; For healthy volunteers:; Subjects not receiving immunosuppressive therapy; For subjects with Sjögren's syndrome:; Subjects not receiving immunosuppressive therapy; For MS patients:.